Cargando…

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US

IMPORTANCE: COVID-19 and seasonal influenza vaccines are essential in preventing respiratory infections and their potentially severe complications. Simultaneous administration of vaccines is efficient and may improve coverage with each vaccine. However, the safety of simultaneous administration of C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hause, Anne M., Zhang, Bicheng, Yue, Xin, Marquez, Paige, Myers, Tanya R., Parker, Casey, Gee, Julianne, Su, John, Shimabukuro, Tom T., Shay, David K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287747/ https://www.ncbi.nlm.nih.gov/pubmed/35838667 http://dx.doi.org/10.1001/jamanetworkopen.2022.22241

Ejemplares similares

Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system
por: Chapin-Bardales, Johanna, et al.
Publicado: (2021)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023
por: Hause, Anne M., et al.
Publicado: (2023)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months–5 Years — United States, June 18, 2022–August 21, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe
por: Rosenblum, Hannah G, et al.
Publicado: (2022)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months–5 Years — United States, June 17, 2022–May 7, 2023
por: Hause, Anne M., et al.
Publicado: (2023)

Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults
por: Tompkins, Lindsay K., et al.
Publicado: (2022)

Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021
por: Shay, David K., et al.
Publicado: (2021)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States
por: Abara, Winston E., et al.
Publicado: (2023)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
por: Parés-Badell, Oleguer, et al.
Publicado: (2022)

COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020–January, 2022: an observational cohort study
por: Wong, Karen K, et al.
Publicado: (2022)

The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC’s COVID-19 pandemic response
por: Myers, Tanya R., et al.
Publicado: (2023)

REACTOGENICITY OF HETEROLOGOUS MRNA-BASED COVID-19 VACCINE BOOSTER IN YOUNG ADULTS IN INDONESIA- A SHORT COMMUNICATION.
por: Neneng, SURYADINATA, et al.
Publicado: (2023)

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
por: Sablerolles, Roos S.G., et al.
Publicado: (2022)

First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021
por: Gee, Julianne, et al.
Publicado: (2021)

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
por: Lee, Jisun, et al.
Publicado: (2023)

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
por: Shimabukuro, Tom T., et al.
Publicado: (2021)

1639. A Review of Clinical Safety, Reactogenicity, and Immunogenicity of an mRNA-Based Seasonal Influenza Vaccine (mRNA-1010) in Adults
por: Soens, Mieke, et al.
Publicado: (2023)

Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial
por: Schmader, Kenneth E., et al.
Publicado: (2021)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Estimated US Pediatric Hospitalizations and School Absenteeism Associated With Accelerated COVID-19 Bivalent Booster Vaccination
por: Fitzpatrick, Meagan C., et al.
Publicado: (2023)

Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2023)

Rates of and Factors Associated With Primary and Booster COVID-19 Vaccine Receipt by US Veterans, December 2020 to June 2022
por: Bajema, Kristina L., et al.
Publicado: (2023)

Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children
por: Dicko, Alassane, et al.
Publicado: (2013)

2395. An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA (samRNA) COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults
por: Whitaker, Jennifer, et al.
Publicado: (2023)

The how’s and what’s of vaccine reactogenicity
por: Hervé, Caroline, et al.
Publicado: (2019)

Reactogenicity of mRNA- and Non-mRNA-Based COVID-19 Vaccines among Lactating Mother and Child Dyads
por: Jacob-Chow, Beth, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of the Booster Dose of COVID-19 Vaccines and Related Factors: A Panel Study from the General Population in Serbia
por: Stosic, Maja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9s9j8afqhpkshbdnot2his2ig6